Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 6/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CBX7 | O95931 | 1/20 | 0.47 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.47 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.47 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25307601 | 0.88 | L3MBTL1 (0.58) | CBX7CDYL2CDYLCDY1; CDY1BALDH1A1 | |
| SCHEMBL782891 | 0.80 | SIGMAR1 (0.57) | KMOSIGMAR1CBX7CDYL2CDYL | |
| SCHEMBL3405552 | 0.78 | KAT2B (0.43) | ALDH1A1 | |
| SCHEMBL22314927 | 0.77 | KMO (0.49) | KMOEGFRALDH1A1 | |
| SCHEMBL26614669 | 0.77 | SIGMAR1 (0.54) | KMOSIGMAR1CBX7CDYL2CDYL | |
| SCHEMBL30336433 | 0.77 | SIGMAR1 (0.53) | SIGMAR1CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL616373 | 0.77 | SIGMAR1 (0.53) | SIGMAR1CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL289808 | 0.77 | SIGMAR1 (0.54) | KMOEGFRSIGMAR1CBX7CDYL2 | |
| SCHEMBL30214704 | 0.77 | SIGMAR1 (0.54) | KMOEGFRSIGMAR1CBX7CDYL2 | |
| SCHEMBL16932296 | 0.75 | CBX7 (0.60) | SIGMAR1CBX7CDYL2CDYLCDY1; CDY1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | KMO 2000/4885EGFR 4618/4885SIGMAR1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.